Dividends Inside Welcome to Dividends Inside
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Welcome to Dividends Inside!
The platform is currently in beta, so some features and data may still change as we improve the service. If you have questions, feedback, or run into anything unexpected, please contact us at info@dividendsinside.com.
Unknown
AKTS
$18.50 (+ $0.00 + 0.00%)
Last updated: Previous Close (2026-05-19)
About the Company
N/A
Price History
Latest News for AKTS
Why This Biotech Fund Opened a $9 Million Position in a Newly Public Cancer Company
This clinical-stage biotech develops targeted radiopharmaceutical therapies for cancer using a proprietary miniprotein platform.
Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
Announced two-trial clinical development strategy for AKY-2519 enabling evaluation in multiple patient segmentsInitiated Phase 1b clinical trial of AKY-2519 in metastatic castration-resistant prostate cancer (mCRPC); expect preliminary data in 2027Announced AKY-2519 clinical imaging and dosimetry data presentation at upcoming 2026 ASCO Annual MeetingEnrolling patients with Nectin-4 expressing tumors in ongoing Phase 1b clinical trial of AKY-1189; expect preliminary data in first quarter 2027 BOS
Aktis Oncology to Present at the BofA Securities Health Care Conference
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Aktis Oncology, Inc. (NASDAQ:AKTS) (the “Company”), a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large populations, including those not addressed by existing platform technologies, today announced that Matthew Roden, Ph.D., President and Chief Executive Officer of Aktis Oncology, will present at the BofA Securities Health Care Conference in Las Vegas, Nevada. The presentation will ta
Aktis Oncology Details Two-Phase 1b Plan for AKY-2519 in Prostate Cancer and Solid Tumors
Aktis Oncology (NASDAQ:AKTS) outlined its clinical development strategy for AKY-2519, a B7-H3 targeted miniprotein radioconjugate, emphasizing a two-trial approach intended to generate indication-specific data in metastatic castration-resistant prostate cancer (mCRPC) while also exploring broader po
Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clinical development strategy includes an mCRPC-dedicated Phase 1b trial in PLUVICTO®-naïve and -experienced patients, and a second Phase 1b basket trial in other B7-H3 expressing solid tumorsTwo-trial strategy enables evaluation of AKY-2519 in broader patient segments and efficient generation of indication-relevant data; preliminary mCRPC data expected in 2027 Aktis to hold conference call tomorrow, Tuesday, May 5, 2026, at 8 a.m. ET to discuss its clinical development strategy for AKY-2519 BOS
Aktis Oncology (AKTS) Valuation Check After A Recent 40% One Month Share Price Jump
Key recent performance snapshot Aktis Oncology (AKTS) has drawn investor attention after a recent one-month return of about 40%, contrasting with a small decline over the past three months and a modest year-to-date loss. The clinical-stage company, focused on targeted radiopharmaceuticals for solid tumors, currently has a market value of about US$1.18 billion and last closed at US$21.26 per share. See our latest analysis for Aktis Oncology. For context, the recent 40% 1 month share price...